IL6 and depressive disorder: This may be important as in a recently completed study of Sukuma (anti-IL-6 monoclonal antibody) in patients with MDD, while there was no significant difference in overall depression severity between sirukumab and placebo, sirukumab was more effective than placebo in reducing severity of anhedonia [40].